GLP-1 Clinical Trial Consent Form: 7 Questions to Ask First

Before joining a GLP-1 clinical trial, ask seven things: what is being tested and how; your chance of getting placebo; the known and unknown risks; what it costs you and what you are paid; what happens with pregnancy and contraception; who sees your data; and what happens when you leave or the study ends. U.S. rules already require the consent form to cover most of these, so you are mostly asking the team to say it in plain English.

You are allowed to take your time, take the form home, bring someone with you, and say no. Saying no, or leaving later, cannot cost you benefits you are otherwise entitled to. That is in the regulations too.

What must a U.S. consent form include?

For FDA-regulated trials, 21 CFR 50.25 lists eight basic elements every consent must contain:

1. That the study is research, its purpose, how long you will be in it, the procedures, and which ones are experimental
2. Reasonably foreseeable risks or discomforts
3. Expected benefits to you or others
4. Appropriate alternative treatments
5. How your records are kept confidential, including that FDA may inspect them
6. For studies with more than minimal risk: whether there is compensation and medical treatment if you are injured
7. Whom to contact with questions, about your rights, and about research injuries
8. That participation is voluntary and you can withdraw at any time without penalty

There are additional elements "when appropriate," such as unforeseeable risks to a pregnancy, costs to you, what happens if you withdraw, how new findings will be shared, and how many people are in the study. Consent forms for applicable trials must also state that a description of the trial will be available on ClinicalTrials.gov.

So if something on this list is missing or vague in your form, that is a fair thing to point out.

The 7 questions, with GLP-1 twists

1. What exactly is being tested, and is it approved for this use?

Is the drug already approved (like semaglutide or tirzepatide) but being tested for a new purpose, a new dose, or a new form? Or is it investigational, meaning not approved for anything yet? Ask what phase the study is in. An approved molecule in a trial is still being used under a research protocol, with research rules. (Investigational vs approved.)

2. What are my odds of getting placebo, and could I be switched later?

Ask for the actual ratio. In STEP 1, participants were randomized 2:1, so one in three got placebo. In SURMOUNT-1, randomization was 1:1:1:1 across three doses and placebo, so one in four got placebo. Some trials are trickier: in SURMOUNT-4, everyone took tirzepatide for 36 weeks, then half were switched to placebo for 52 weeks, and that group's weight went back up by an average of 14%. If a study has a design like that, you deserve to know before you start.

3. What risks are known, and what is still unknown?

For approved GLP-1 drugs, the label lists the known risks, such as nausea, vomiting, diarrhea, gallbladder problems and pancreatitis. For investigational drugs, ask what has been seen so far and in how many people. Ask what side effects should make you call the study team, and how fast you can reach someone, including at night.

4. What will it cost me, and what will I be paid?

Ask which visits, tests and medicines are covered, whether your insurance will be billed for anything, and what happens if you are injured. Ask about payment for time, parking and travel. Payment is fine; FDA guidance says ads should not make payment the main attraction, and neither should the consent conversation.

5. What are the rules on pregnancy and contraception?

GLP-1 trials usually exclude pregnancy and often require contraception. This matters more than usual with tirzepatide: the Zepbound label advises people using oral contraceptives to switch to a non-oral method, or add a barrier method, for 4 weeks after starting and for 4 weeks after each dose increase, because the label says delayed stomach emptying may make the pill less effective. Ask what methods the study accepts and what happens if you become pregnant. (Tirzepatide and birth control pills.)

6. What data and samples are collected, and who sees them?

Ask what is stored, for how long, whether samples might be used for future research, and whether you will get your own results (like lab values or body scans). Ask whether anything goes to your regular doctor.

7. What happens if I leave, or when the study ends?

Ask what follow-up visits they would request if you withdraw, and what happens to data already collected. Then the big one for weight trials: will I be able to continue the medicine after the study? In STEP 1, both semaglutide and the lifestyle program stopped at week 68, and the extension found people regained about two-thirds of their lost weight in the following year. Know the plan before you start. (Extension studies explained.)

Printable consent-visit checklist

Copy this into your notes or print it for the visit.

✓	Question	Answer from study team
☐	Study name and NCT number
☐	What is being tested? Approved or investigational? Phase?
☐	My chance of placebo? Any planned switch to placebo?
☐	How many visits, how long, total duration?
☐	Main known risks; who to call, 24/7 number
☐	What is free, what might be billed, what is paid?
☐	Injury: what care is provided and who pays?
☐	Contraception rules; what if I get pregnant?
☐	Data and samples: stored where, used for what, shared with my doctor?
☐	If I withdraw: follow-up requested, data kept?
☐	After the study: can I keep taking the drug?
☐	Will I be told the overall results?

A few habits that help

• Bring a second person. One of you listens, one writes.
• Ask them to explain it back. "So in plain words, what happens at week 36?" is a perfectly good question.
• Check the record yourself. Look up the NCT number on ClinicalTrials.gov and compare it with what you were told. (How to find and check a recruiting GLP-1 trial.)
• Keep your own log. Study teams record a lot, but your own notes of symptoms and questions between visits help. If you use GLPily, the journal and symptom log work well for that; just follow the team's instructions on what to report and how.

Common questions

Can I take a clinical trial consent form home before signing?

Generally yes, and it is a good idea. Ask for a copy, read it at home, and come back with questions.

Can I leave a GLP-1 trial whenever I want?

Yes. Participation is voluntary and you can withdraw at any time without penalty or loss of benefits you are otherwise entitled to. Ask what follow-up they would like and how stopping the drug should be handled safely.

Will I definitely get the real drug?

Not in a placebo-controlled study. Ask for your exact odds and whether any phase switches people to placebo.

Who reviews whether a trial is ethical?

An institutional review board (IRB) reviews and approves the study, its consent form and its recruitment materials before enrollment.